![[PDF]](/pb-assets/Icons/adobe-pdf-icon-1498649896243.png){kind=icon}
Abstract
This article investigates whether Asian countries are becoming more active at the discovery stage, a higher stage of the drug development value chain. We conduct the first quantitative study to investigate these countries positioning in drug discovery activities. For this purpose, we draw on a database containing historical information on more than 61,000 drugs, for the period 1994–2015, and extract and analyse data on the drug discovery events in which a selected group of Asian countries were involved.
The results show that these countries are increasingly involved in activities of discovery and that, in some of them, these activities are predominantly conducted on drugs owned by local organisations. Along with this process, markets for discovery are being created, both through sub-contracting and through partnerships among local organisations (for their own drugs) and between local and non-local ones. Second, drawing on the strategies and organisational set-ups adopted in each country, we distinguish a number of profiles regarding the ways competences for markets for discovery are being built. Third, we identify the existence of a strong regional centre of competences, acting as a local–global articulation locus for markets of discovery.
These results provide new insights into the ways Asian countries are moving up the drug development value chain and contribute to our understanding of the learning processes underway in different contexts and the variety of configurations resulting from these processes, supporting a discussion on the potential role of policies to further expand markets for discovery.
References
| Abrami, R. M., Kirby, W. C., McFarlan, F. W. (2014). Why China can’t innovate. Harvard Business Review, 92(3), 107–111. Google Scholar | |
| Boutellier, R., Ullman, F. (2007). China’s unique position in discovery and preclinical research. Drug Discovery Today, 12(1), 4–7. Google Scholar | Medline | |
| Chaturvedi, K., Chataway, J. (2006). Strategic integration of knowledge in Indian pharmaceutical firms: Creating competencies for innovation. International Journal of Business Innovation and Research, 1(1, 2), 27–50. Google Scholar | |
| Clark, D. E. (2011). Outsourcing lead optimization: The eye of the storm. Drug Discovery Today, 16(3), 147–157. Google Scholar | Medline | |
| Collins, F. S. (2011). Reengineering translational science: The time is right. Science Translational Medicine, 3(90), 1–6. Google Scholar | ISI | |
| Deloitte (2011). The next phase: Opportunities in China’s pharmaceuticals market. Retrieved from http://www2.deloitte.com/content/dam/Deloitte/ch/Documents/life-sciences-health-care/ch_Studie_Pharmaceutical_China_05052014.pdf Google Scholar | |
| Filatotchev, I., Liu, X., Lu, J., Wright, M. (2011). Knowledge spillovers through human mobility across national borders: Evidence from Zhongguancun Science Park in China. Research Policy, 40(3), 453–462. Google Scholar | ISI | |
| Finegold, D., Wong, P. K., Cheah, T. C. (2004). Adapting a foreign direct investment strategy to the knowledge economy: The case of Singapore’s emerging biotechnology cluster. European Planning Studies, 12(7), 921–941. Google Scholar | ISI | |
| Jackson, M. O. (2010). Social and economic networks. Princeton, NJ: Princeton University Press. Google Scholar | Crossref | |
| Jia, H. (2007). Chinese manufacturers vie for piece of outsourcing pie. Nature Biotechnology, 25(12), 1337–1338. Google Scholar | Medline | |
| Medina-Franco, J. L., Giulianotti, M. A., Welmaker, G. S., Houghten, R. A. (2013). Shifting from the single to the multitarget paradigm in drug discovery. Drug Discovery Today, 18(9), 495–501. Google Scholar | Medline | |
| Mucke, H. A. (2015). A new journal for the drug repurposing community. Drug Repurposing, Rescue, and Repositioning, 1(1), 3–4. Google Scholar | |
| Nature . (2016). Science in China. Nature 534 (special issue), 451. Google Scholar | Medline | |
| Novac, N. (2013). Challenges and opportunities of drug repositioning. Trends in Pharmacological Sciences, 4(5), 267–272. Google Scholar | |
| Oprea, T. I., Mestres, J. (2012). Drug repurposing: Far beyond new targets for old drugs. The AAPS Journal, 14(4), 759–763. Google Scholar | Medline | |
| Padma, T. V. (2015). India: The fight to become a science superpower. Nature, 521(7551), 144–147. Google Scholar | Medline | |
| Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R. . (2010). How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery, 9(3), 203–214. Google Scholar | Medline | ISI | |
| PricewaterhouseCoopers (2008). The changing dynamics of pharma outsourcing in Asia: Are you readjusting your sights? Retrieved from https://www.pwc.be/en/pharma/the-changing-dynamics-of-pharma-outsourcing-in-asia.pdf Google Scholar | |
| PricewaterhouseCoopers (2010). Pharmaceuticals and life sciences global pharma looks to India: Prospects for growth. Retrieved from http://www.pwc.com/gx/en/industries/pharmaceuticals-life-sciences/publications/india-growth.html Google Scholar | |
| Rafols, I., Hopkins, M. M., Hoekman, J., Siepel, J., O’Hare, A., Perianes-Rodríguez, A. . (2014). Big pharma, little science? A bibliometric perspective on Big Pharma’s R&D decline. Technological Forecasting and Social Change, 81, 22–38. Google Scholar | |
| Ray, A. S. (2004). The changing structure of R&D incentives in India: The pharmaceutical sector. Science Technology & Society, 9(2), 295–317. Google Scholar | SAGE Journals | |
| Ray, A. S., Bhaduri, S. (2014). The Indian pharmaceutical industry: Policy space that fosters technological capability. In Drache, D., Jacobs, L. (Eds), Linking global trade and human rights: New policy spaces in hard economic times (pp. 174–194). New York, NY: Cambridge University Press. Google Scholar | |
| Reichman, M., Simpson, P. B. (2016). Open innovation in early drug discovery: Roadmaps and roadblocks. Drug Discovery Today, 21(5), 779–788. Google Scholar | Medline | |
| Sariola, S., Ravindran, D., Kumar, A., Jeffery, R. (2015). Big-pharmaceuticalisation: Clinical trials and contract research organisations in India. Social Science & Medicine, 131, 239–246. Google Scholar | Medline | |
| Shi, T., Chang, X., Tang, J., Zheng, Z. (2016). Driving force from authorities: The evolution of innovation system for biomedical industry in China. Technology Analysis & Strategic Management, 285(10), 1210–1224. Google Scholar | |
| Subramaniam, S., Dugar, S. (2012). Outsourcing drug discovery to India and China: From surviving to thriving. Drug Discovery Today, 17(19, 20), 1055–1058. Google Scholar | Medline | |
| Thomson Reuters (2013). The new patent dynasty. Retrieved from http://ip.thomsonreuters.com/sites/default/files/new-patent-dynasty.pdf Google Scholar | |
| Xia, C., Gautam, A. (2015). Biopharma CRO industry in China: Landscape and opportunities. Drug Discovery Today, 20(7), 794–798. Google Scholar | Medline | |
| Yu, H. (2015). Universal health insurance coverage for 1.3 billion people: What accounts for China’s success? Health Policy, 119(9), 1145–1152. Google Scholar | Medline | ISI | |
| Zhou, Y. (2007). Opportunities in biopharmaceutical outsourcing to China. BioProcess International, 5(1), 16–23. Google Scholar |
